|
Enter your information below to register with the Talecris Cares Program. Enroll now and you can receive updates about alpha1-antitrypsin (AAT) deficiency and Prolastin®, as well as our free newsletter.
By providing your name, address, telephone number, and other information, you are giving Talecris Biotherapeutics and companies working with Talecris Biotherapeutics permission to provide information to you related to alpha1-antitrypsin deficiency, including marketing or advertising for our products and services. Talecris Biotherapeutics will not sell or transfer your name, address, telephone number, or e-mail address to any other party for their own marketing use.
*Indicates required information.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|